Fluidigm Corporation develops, manufactures, and markets microfluidic systems for academic research institutions, clinical laboratories, pharmaceutical companies, and biotechnology and Ag-Bio companies. Its proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits (IFCs), assays, and other reagents. The company’s products include BioMark HD system that performs high-throughput gene expression analysis, single-cell gene expression analysis, single nucleotide polymorphism (SNP) genotyping, and digital polymerase chain reaction (PCR) using Fluidigm DELTAgene and SNPtype assays, other chemistries, and Fluidigm dynamic array and digital array IFCs; and EP1 system that performs SNP genotyping using Fluidigm SNPtype assays or TagMan assays, as well as end-point digital PCR using TaqMan assays, and Fluidigm Dynamic Array and Digital Array IFCs. Its products also comprise C1 Single-Cell Auto Prep system, which enables rapid and reliable isolation, processing, and profiling of individual cells for genomic analysis for various applications, such as targeted single-cell gene expression and single-cell messenger ribonucleic acids analysis; and Access Array system that enables automated sample preparation, barcoding, and tagging of targeted resequencing libraries. In addition, the company offers dynamic array, digital array, C1 single-cell auto prep array, and access array IFCs; and DELTAgene and SNPtype assays, and access array target-specific primers. Fluidigm Corporation distributes its systems through direct sales force and support organizations in North America, Europe, and the Asia-Pacific; and through distributors or sales agents in Europe, Latin America, the Middle East, and the Asia-Pacific countries. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

Key Statistics